Skip to main
AVXL

AVXL Stock Forecast & Price Target

AVXL Analyst Ratings

Based on 2 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Anavex Life Sciences is seen as a prospect for investors, as it engages in the development of precision medicine for neurodegenerative and neurodevelopmental diseases with high unmet need. The company has a strong pipeline, including ANAVEX 2-73 and ANAVEX 3-71, and continues to engage with the FDA and EMA on their regulatory pathway, reinforcing the belief that the U.S. remains the primary value driver. With clinical data showing potential for neuroprotection and convenience of administration, Anavex Life Sciences may have a strong chance of success, which is reflected in our $24.0 price target and use of a 30% discount rate in our valuation.

Bears say

Anavex Life Sciences is faced with a challenging future as the company expands into multiple indications beyond Alzheimer’s disease, including Parkinson’s disease and Rett syndrome. Their current valuation is impacted by lowered therapeutic success probabilities in the US and EU markets, supported by a discounted cash flow model, discounted earnings per share model and a sum-of-the-parts analysis.

AVXL has been analyzed by 2 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Anavex Life Sciences and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Anavex Life Sciences (AVXL) Forecast

Analysts have given AVXL a Strong Buy based on their latest research and market trends.

According to 2 analysts, AVXL has a Strong Buy consensus rating as of May 20, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $22, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $22, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Anavex Life Sciences (AVXL)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.